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Environmental and occupational disorders
Diesel exhaust particles exert acute
effects on airway inflammation and
function in murine allergen provocation
models
Minqi Hao, MD, PhD,a Stephania Comier, PhD,b Meiying Wang, MD,a
James J. Lee, PhD,b and Andre Nel, MD, PhDa Los Angeles, Calif, and Scottsdale, Ariz
Background: Epidemiologic studies show that sudden surges
in ambient particulate matter (PM) levels can trigger acute
asthma exacerbations. Although diesel exhaust particles
(DEPs) act as an adjuvant for allergic sensitization, this is a
delayed response and does not explain acute PM effects on air-
way hyperreactivity (AHR).
Objective: Our aim was to determine the acute effects of DEPs
on AHR using a mouse model.
Methods: Three protocols were developed, 2 of which require
OVA sensitization, whereas the third was OVA independent. In
the mild sensitization protocol BALB/c mice receive intraperi-
toneal OVA without alum and are then challenged with
aerosolized OVA with or without DEPs. In the postchallenge
model DEPs are delivered after OVA challenge to animals sen-
sitized by intraperitoneal OVA plus alum. In the third protocol
nebulizer DEPs were also delivered to IL-5–overexpressing
mice that exhibit constitutive airway inflammation. Animals
were subjected to whole-body plethysmography (WBP) and
then killed for performance of bronchoalveolar lavage, histol-
ogy, and serology.
Results: DEP delivery concomitant with OVA challenge or
after the induction of airway inflammation with this allergen
induced increased AHR in models 1 and 2, respectively.
Although these animals showed DEP-induced inflammation
and mucus production in the intermediary airways, there was
no effect on OVA-specific IgE or TH2 cytokine production. In
the IL-5 transgenic mice it was possible to induce similar
effects with DEPs in the absence of an allergen.
Conclusion: We demonstrate that DEPs induced AHR inde-
pendent of their adjuvant effects, suggesting the use of these
models to study the mechanism or mechanisms of acute asth-
ma exacerbation by means of PM. (J Allergy Clin Immunol
2003;112:905-14.)
Key words: Diesel exhaust particle, airway hyperreactivity, asth-
ma, mouse models
Recent epidemiologic studies have reported an associa-
tion between short-term increases in ambient particulate
matter (PM) levels and acute cardiorespiratory events,
including acute asthma flares.1,2 Although the exact mech-
anism or mechanisms of these effects are unknown, there is
accumulating evidence from controlled-exposure studies
that PM induces acute inflammation in the human lung.3
This is consistent with data showing that diesel exhaust
particles (DEPs) act as an adjuvant for allergen sensitiza-
tion in animals and human subjects.4,5 These effects are
dependant on redox cycling DEP chemicals that exert pro-
oxidative and pro-inflammatory effects in the lung.6
Although the adjuvant effects of PM could affect asth-
ma prevalence in the long term,7 this does not explain
acute asthma flares within a few hours after the pollution
event.2 This suggests that in addition to their subacute or
chronic effects, DEPs exert acute effects on airway
hyperreactivity (AHR). Almost all of the animal proto-
cols used to date to show that DEPs affect AHR have
been long-term studies in which either the particles are
directly delivered to the trachea or nose or the animals
are exposed to diesel fumes in an inhalation chamber for
extended time periods (6-16 weeks).8-15 This limits the
use of these protocols in studying PM effects on asthma.
We used a classical sensitization approach (intraperi-
toneal OVA plus aluminum hydroxide) to determine
whether DEPs coadministered with OVA exert effects on
AHR in BALB/c mice. Because this did not lead to a dis-
cernable increase in OVA-induced AHR, we developed
alternative approaches to studying short-term DEP
effects in mice. Success was achieved with a milder OVA
sensitization model16 in which aerosolized DEPs could
induce increased AHR without enhancing IgE produc-
tion. We also demonstrated that DEPs could induce
increased AHR and mucin production if delivery of the
nebulizer particles is delayed until after the peak airway
inflammatory response. DEPs could also induce AHR in
animals with constitutive airway inflammation caused by
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transgenic IL-5 overexpression, suggesting that DEP
exposure is capable of exacerbating ongoing inflamma-
tory responses in the absence of allergen provocation.
MATERIALS AND METHODS
DEP source and preparation
Light-duty DEPs collected from a 4-cylinder Isuzu diesel engine
under a 10-torque load in a cyclone impactor were obtained from Dr
Masaru Sagai (National Institute of Environment Studies, Tsukuba,
Ibaraki, Japan). The DEP stock was prepared by resuspending 100
mg of particles in 10 mL of PBS, followed by vortexing and dis-
persion with a sonic disrupter for 10 minutes on ice.6
Animal sensitization and exposure
conditions
Six- to 7-week-old female BALB/c mice were obtained from
Charles River Laboratories (Hollister, Calif). NJ.1726 mice
(C57BL/6J background) that exhibit transgenic IL-5 expression in
the lung epithelium were generated as previously described.17 Mice
were housed in filter-topped cages under standard laboratory condi-
tions and maintained on autoclaved food and acidified water.
For the mild sensitization protocol, animals received 20 µg of
OVA without alum in 500 µL of PBS intraperitoneally on day 1 (Fig
1, A).16 The negative control group (group 1) received 500 µL of
PBS, whereas the positive control group (group 2) received 20 µg
of OVA plus 2 mg of alum in 500 µL of PBS intraperitoneally. Each
group included 6 animals. All mice were exposed on days 14 to 17
to nebulized saline (group 1), saline for an hour followed by 1%
OVA (20 minutes; group 2), 2 mg/m3 DEPs for an hour followed by
1% OVA (20 minutes; group 3), or saline for an hour followed by
1% OVA (20 minutes; group 4). OVA and DEP nebulization was
performed with a Schuco 2000 (Allied Health Care Products, St
Louis, Mo), which delivers 0.5- to 4-µm particles at a flow rate of 6
L/min.6 The animals were subjected to whole-body plethysmogra-
phy (WBP) on day 18 and were killed on day 19. NJ.1726 mice
were exposed to nebulized saline or 200 µg/m3 DEPs for 1 hour
daily for 3 days, used for WBP, and killed for sample collection on
day 5 (Fig 4, A).
All animal groups in the postchallenge model, with the excep-
tion of the negative control group, received 20 µg of OVA plus 2 mg
of alum intraperitoneally on day 1 (Fig 6, A). Thereafter, the ani-
mals were challenged with nebulizer saline or 1% OVA daily for 20
minutes on days 15 to 17, after which the animals received nebuliz-
er saline, 1% OVA (20 minutes), or 2 mg/m3 DEPs for 1 hour daily
on days 18 to 21 (Fig 6, A). The animals were used for WBP on day
22 and killed on day 23.
Determination of airway responsiveness
Total pulmonary airflow in unrestrained conscious mice was
estimated with a WBP device (Buxco Electronics, Troy, NY).17,18
Mice were challenged for 2 minutes with a series of aerosolized
methacholine administrations. Pressure differences between the
chambers containing individual animals and a reference chamber
were used to extrapolate minute volume, tidal volume, breathing
frequency, and enhanced pause (PenH).18 Airway reactivity was
monitored for 3 minutes after each aerosol challenge. PenH is a
function of total pulmonary airflow during the respiratory cycle and
is described by the following equation:
PenH = (PEP/PIP) × pause,
where PEP is the peak expiratory pressure, PIP is the peak inspi-
ratory pressure, and pause is a component of expiration time. This
parameter is dependent on the breathing pattern and correlates with
airway resistance as measured by traditional invasive techniques
with ventilated mice.18
Animal death and sample collection
Mice were killed by administering pentobarbital intraperitoneal-
ly. Blood was collected by means of cardiac puncture. The trachea
was cannulated, and the lungs were gently lavaged 3 times with 1
mL of sterile PBS to obtain bronchoalveolar lavage (BAL) fluid.
Lungs were expanded with 10% buffered formalin phosphate before
excision and sectioning. The BAL fluid was centrifuged at 1000
rpm for 10 minutes, and total and differential cell counts were per-
formed as previously described.6,17
Determination of OVA-specific IgE and IgG1
antibody titers
Serum OVA-specific IgE and IgG1 levels were measured by
means of ELISA, as previously described.6
Lung histology and immunohistochemistry
Lung sections were stained with hematoxylin and eosin and peri-
odic acid–Schiff stain.17 For conducting major basic protein (MBP)
immunohistochemistry, tissue sections were deparaffinized, fol-
lowed by quenching of endogenous peroxidase activity, blocking
with 1% normal goat serum, and sequential overlay with rabbit anti-
MBP (1:1000) antibody and goat anti-rabbit antibody.19 Staining
was conducted by using Vectastain Elite ABC and DAB kits (Vec-
tor Laboratories, Burlingame, Calif).
Statistical analysis
All data were expressed as means ± SD or means ± SEM. Dif-
ferences between groups were evaluated by means of ANOVA. If
differences between groups were significant (P < .05), the Student t
test was used to distinguish between pairs of groups. A P value of
less than .05 was considered significant.
RESULTS
Use of a mild sensitization model to
demonstrate DEP effects on AHR
Delivery of aerosolized DEPs concomitant with OVA
challenge in animals sensitized with intraperitoneal OVA
plus alum did not affect OVA-specific IgE production,
BAL eosinophilia, or methacholine-induced AHR (data
not shown). This suggests that in this model OVA alone
induced a near-maximal response that does not leave room
for a superimposed DEP effect. This hypothesis was test-
ed by using a mild sensitization protocol that involves sub-
maximal responses after allergen provocation.16 The mild
protocol was accomplished by eliminating the TH2 adju-
vant, alum, from the intraperitoneal sensitization protocol
Environm
ental and
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Abbreviations used
AHR: Airway hyperreactivity
BAL: Bronchoalveolar lavage 
DEP: Diesel exhaust particle
MBP: major basic protein
OVA: Ovalbumin
PenH: Enhanced pause
PM: Particulate matter
WBP: Whole-body plethysmography
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(Fig 1, A). Relative to animals sensitized with OVA plus
alum (group 2), the mildly sensitized animals (groups 3
and 4) showed a smaller increase in BAL eosinophil
counts (Fig 1, B) and OVA-specific antibody production
(Fig 1, C). No discernible increase in the levels of IL-4, IL-
5, IL-13, and GM-CSF were seen in the BAL fluid during
DEP treatment, although group 2 did show a statistically
significant increase in IL-13 levels (Table I). Although
DEP coadministration did not significantly enhance BAL
eosinophilia and OVA antibody titers (Fig 1, C; group 3),
DEPs did induce a significant (P < .05) increase in metha-
choline-induced AHR (Fig 2, group 3).
A
B
C
FIG 1. Use of a mild sensitization protocol to show the effects of nebulizer DEPs on AHR and inflammation.
A, Outline of the protocol. B, Total and differential BAL cell counts. C, Serum OVA-specific antibody levels,
as determined by means of ELISA. *P < .05, groups 3 and 4 versus group 2.
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Histologic assessment of lung tissue samples from
each group revealed that peribronchial and perivascular
inflammatory cell infiltrates were less prominent in the
mild compared with the classical sensitization model (Fig
3, A, panels a-d). Although DEPs did not affect small air-
ways, aerosolized particles did induce foci of inflamma-
tion associated with large and intermediary airways (Fig
3, A, panels c-e). These changes were accompanied by
increased MBP deposition, as well as an influx of MBP-
positive eosinophils in the mucosa (Fig 3, B). DEP treat-
ment also induced increased mucin staining in large and
intermediary airways in sensitized (panel c) compared
with saline-treated (panel d) animals (Fig 3, C).
Taken together, these data indicate that DEPs induce
AHR and airway inflammation without affecting the
magnitude of the anti-OVA response. This raises the
question as to whether DEPs can induce AHR indepen-
dent of an allergen.
IL-5 transgenic mice show that DEPs can
affect AHR independent of an allergen
We have previously shown that transgenic mice with
constitutive IL-5 expression in the lung leads to accumu-
lation of peribronchial eosinophils, as well as an expan-
sion of bronchus-associated lymphoid tissue, goblet cell
hyperplasia, epithelial hypertrophy, and focal collagen
deposition.17 This provides us with a model to study DEP
effects in the absence of allergen challenge. Exposure of
these animals to aerosolized DEP daily for 3 days (Fig 4,
A) resulted in increased AHR compared with that of ani-
mals receiving saline only (Fig 4, B). This was not
accompanied by changes in the BAL cell count, which is
constitutively increased in this model (not shown). No
change in BAL cytokine levels occurred during DEP
treatment (not shown). However, as for the mild sensiti-
zation model, IL-5 transgenic mice responded to DEP
administration with increased airway inflammation and
mucin production in large and intermediary airways (Fig
5, A and B). Because these data show that DEPs affect
AHR independent of an allergen, this raises the question
of whether DEPs can exert similar effects after the dissi-
pation of the allergen-dependant effect.
Delayed DEP delivery induces AHR and
mucin production in the classical
sensitization model
In a modification of the classical OVA sensitization and
challenge model, mice were sensitized to intraperitoneal
OVA and alum, challenged with aerosolized OVA on days
15 to 17, and then treated with aerosolized saline or DEPs
for 4 days (Fig 6, A, groups 2 and 5, respectively). Penh
was measured on day 22, and sample collection occurred
on day 23 (Fig 6, A). The negative controls included ani-
mals receiving intraperitoneal PBS followed by
aerosolized saline on days 15 to 21 (group 1) or sensitized
animals receiving saline on days 15 to 17 and DEPs on
days 18 to 21 (group 4). The positive control group was
sensitized animals receiving OVA on days 18 to 21 (group
3). Statistically significant (P < .05) methacholine-
induced AHR was observed when comparing group 3
with group 1, whereas the AHR in group 2 declined to
near-basal values (Fig 6, B). There was no response in
animals receiving DEPs without prior OVA challenge
(group 4), although animals receiving OVA challenge on
days 15 to 17, followed by DEPs on days 18 to 21 (group
5), showed a statistically significant increase in AHR
compared with that seen in groups 2 and 4 (Fig 6, B).
Examination of the BAL fluid showed the expected
increase in total and differential cell counts in the posi-
tive control group (group 3, Table II). The increase in
BAL cell counts in groups 2 and 5 was smaller but with-
out a discernible DEP effect (Table II). Similarly, there
was a smaller increase in the OVA-specific IgE and IgG1
antibody levels (Table III) and the BAL fluid IL-13 lev-
els (Table IV) in groups 2 and 5 compared with that in
group 3. DEPs did not exert any effects on TH2 cytokine
Environm
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TABLE I. BAL cytokines in the mild sensitization model
Cytokines Group 1 Group 2 Group 3 Group 4
IL-13 9.09 ± 0.69 52.33 ± 6.97* 8.81 ± 0.86 13.95 ± 3.56
GM-CSF 4.77 ± 0.39 4.99 ± 0.27 5.49 ± 0.52 5.17 ± 0.56
IL-4 12.85 ± 1.42 14.37 ± 3.09 17.47 ± 0.90 14.90 ± 0.89
IL-5 16.88 ± 0.93 18.82 ± 1.27 26.27 ± 4.83 16.74 ± 4.12
Values are shown as means ± SD in picograms per milliliter.
*P < .05 compared with group 1.
FIG 2. DEP exposure leads to an increase in methacholine-
induced AHR in the mild sensitization protocol. Penh was mea-
sured in a Buxco box, as previously described.17 *P < .05, group
3 versus group 4.
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FIG 3. Histology to show airway inflammation and MBP and mucin staining in the mild sensitization proto-
col. A, Hematoxylin and eosin staining (a, group 1; b, group 2; c and e, group 3; d and f, group 4). B, MBP
staining (a, group 3; b, group 4). (Figure continued on next page.)
A
B
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levels (Table IV). Moreover, tissue histology revealed
less inflammation in the small airways of groups 2 and 5
compared with group 3 (not shown). Similar to the mild
sensitization model (Fig 3), DEP treatment was associat-
ed with increased airway inflammation and mucin pro-
duction in the larger and intermediary airways in group 5
compared with that seen in group 2 (not shown).
DISCUSSION
A number of animal and human studies have demon-
strated that DEPs act as an adjuvant during allergen expo-
sure,4,8-15 raising the possibility that PM might be involved
in the increased prevalence of atopic asthma.4 However,
although there is an epidemiologic link between asthma
prevalence and exposure to polluted urban environments
or vehicular emissions, there are no definitive data to
establish that DEPs play a role in the global asthma epi-
demic.20,21 In addition to these subacute and chronic
effects, PM exposure induces acute asthma exacerbations,
suggesting that PM can effect AHR independent of its
effects on allergic sensitization. This notion is compatible
with the data presented here. We demonstrate that
although allergic airway inflammation is necessary to elic-
it a DEP-induced response in models 1 and 2, the particles
can act independent of the allergen to induce AHR in IL-
5–overexpressing mice. Our study agrees with previous
mouse models in which long-term DEP exposures were
used to demonstrate particle effects in the presence or
absence of an allergen.8-15 A drawback of these long-term
studies is the reliance on intratracheal or intranasal admin-
istration or the necessity to use an exposure chamber to
deliver diesel exhaust fumes over a 12-hour period daily
for 3 to 16 weeks.8-15 Although many of these studies
show a DEP-induced increase in BAL eosinophilia, OVA-
specific IgE production, and increased IL-5 and GM-CSF
production, our experimental models did not show this
adjuvant effect.8-15 Variation of the dose, frequency, and
time of DEP administration did not result in an animal
model in which DEPs increase both the level of OVA sen-
sitization, as well as AHR. Although it is possible to
enhance OVA-specific IgE production in animals receiv-
ing nebulizer DEPs plus OVA,6 these animals do not have
BAL eosinophilia or increased AHR (not shown). There-
fore the shortcomings of the inhalation sensitization model
is that DEPs do not achieve the level of sensitization and
inflammation that is required to induce AHR. Apparently,
it is possible to enhance allergic inflammation and achieve
this threshold during chronic DEP exposure.8-15 These
chronic exposure protocols require a diesel engine and an
exposure chamber, which is costly and not widely avail-
able to investigators in this field.
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FIG 3. (continued) C, Periodic acid–Schiff staining (a, group 1; b, group 2; c, group 3; d, group 4; original
magnification 100×).
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We demonstrate that DEP-induced AHR could be
achieved in 3 different ways. The first model is a mild
OVA sensitization protocol, in which DEP delivery con-
comitant with OVA challenge induces increased airway
obstruction, as well as increased inflammatory changes
and mucin production, in large and intermediary airways
(Figs 1-3). A possible explanation for the effect of nebu-
lizer DEPs on large and intermediary airways is the depo-
sition of the relatively large-sized nebulizer droplets in
these airways. Animals in this protocol did not exhibit an
increase in OVA-specific IgE or TH2 cytokine levels. The
second protocol uses DEP administration to sensitized
animals after they have been exposed to OVA. The
delayed introduction of the nebulizer particles is neces-
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TABLE II. BAL cell counts in the post-OVA challenge model
Group 1 Group 2 Group 3 Group 4 Group 5
Total cell count 0.58 ± 0.10 8.74 ± 1.21 14.51 ± 3.91* 0.70 ± 0.14 7.2 ± 1.89
Eosinophils 0.00 3.52 ± 0.62 7.94 ± 2.66* 0.00 3.83 ± 1.45
Neutrophils 0.00 0.29 ± 0.11 0.26 ± 0.09 0.00 0.08 ± 0.06
Lymphocytes 0.00 1.33 ± 0.33 0.83 ± 0.20 0.004 ± 0.002 0.62 ± 0.16
Monocytes 0.58 ± 0.10 3.60 ± 1.01 5.47 ± 1.15 0.69 ± 0.14 2.66 ± 0.38
Values are shown as means ± SD in cells × 105 per milliliter.
*P < .05 compared with groups 1 and 4.
FIG 4. The effects of nebulizer DEPs on IL-5 transgenic mice: A, protocol outline; B, DEP exposure leads to
an increase in methacholine-induced AHR in IL-5 transgenic mice. *P < .05, DEPs versus saline at 100 mg/mL
methacholine.
A
B
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FIG 5. Histology to show the effects of nebulizer DEPs on lung inflammation. A, Hematoxylin and eosin
staining (a and b, saline exposure; c and d, DEP exposure). B, Periodic acid–Schiff staining (same panels as
Fig 5, A).
A
B
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sary to demonstrate a DEP effect that is otherwise
obscured by the rigorous inflammatory response to OVA
in the classical model. These data are reminiscent of the
acute asthma exacerbations that follow a sudden surge in
PM levels.2,3 The realization that a lesser degree of airway
inflammation is optimal for elucidating DEP effects led to
the introduction of the third model, which uses constitu-
tive eosinophilic inflammation in IL-5 transgenic mice to
elicit AHR and pro-inflammatory effects (Figs 4 and 5).
Our exposure methods should be useful to dissect the
pathways and chemical components by which DEPs
induce acute asthma exacerbations. In addition to enhanc-
ing already existing airway inflammation, DEPs might
also affect AHR by damaging bronchial epithelial cells.22
In this regard we have previously shown that DEPs induce
apoptosis in bronchial epithelial cells in an oxidative
stress-dependent fashion.22 Shedding of epithelial cells
might lead to increased airway reactivity.23 Tunnel stain-
ing of the lung sections from the postchallenge model did
not, however, reveal an increase in the apoptotic cells in
the bronchial epithelial lining of DEP-treated animals (not
shown). Other possible mechanisms of action include
effects on irritant receptors, smooth muscle function,
cytokine production, and autonomic reflexes. An example
of an irritant receptor is the capsaicin receptor, which
might be activated by noxious and tissue-damaging stim-
uli, giving rise to the release of neuropeptides from senso-
ry nerve fibers.24 Because respiratory epithelial cells are
the first to encounter and respond to airborne irritants, it
might be relevant that PM has been shown to initiate
inflammatory cytokine release by the activation of cap-
saicin receptors in a human bronchial epithelial cell line.24
In light of the DEP-induced AHR in IL-5 transgenic ani-
mals, it is also possible that DEP chemicals might affect
eosinophil degranulation and mediator release. Although
aerosolized DEP inhalation per se did not stimulate IL-5
production, it is possible that DEP chemicals might stim-
ulate the release of chemokines that are involved in
eosinophil chemotaxis. In this regard our own studies have
demonstrated induction of RANTES, macrophage inflam-
matory protein 1α, and monocyte chemoattractant protein
3 production in the human nasal mucosa during challenge
with DEPs.25 Our future studies will address the mecha-
nism of DEP-induced AHR in more detail.
In summary, we have shown that DEPs can induce
acute AHR in mice in the absence or presence of an aller-
gen, and we will use this approach to study the PM com-
ponents and biologic pathways by which PM induce
acute asthma exacerbations.
We thank Dr Michael A. O’Reilly (University of Rochester Med-
ical Center) for assistance with Tunnel staining and Mr Marv Ruona
(Mayo Clinic Scottsdale) for graphic assistance.
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TABLE III. Serum OVA-specific Ig levels in the post-OVA challenge model
Group 1 Group 2 Group 3 Group 4 Group 5
IgE (U/mL) 0.00 1044 ± 238 2190 ± 419* 349 ± 86 877 ± 194
IgG1 (ng/mL) 0.00 269 ± 61 1246 ± 368* 55 ± 10 319 ± 72 
Values are shown as means ± SD.
*P < .05 compared with other groups.
TABLE IV. Cytokines in the BAL fluid in the post-OVA challenge model
Cytokines Group 1 Group 2 Group 3 Group 4 Group 5
IL-13 6.84 ± 0.28 24.22 ± 7.83 155.02 ± 40.03* 8.80 ± 1.12 20.03 ± 3.28
GM-CSF 4.36 ± 0.19 4.89 ± 0.14 5.14 ± 0.47 4.50 ± 0.29 4.32 ± 0.11
IL-4 13.35 ± 0.81 18.60 ± 3.99 23.13 ± 2.77 14.40 ± 2.78 21.47 ± 1.88
IL-5 9.46 ± 2.37 18.12 ± 1.02 27.24 ± 6.26 9.60 ± 1.62 11.62 ± 3.38
Values are shown as means ± SD in picograms per milliliter.
*P < .05 compared with other groups.
